DSG Press releases for the clinical trial and life sciences industries

DSG Press Releases

DSG Press Releases – For the eClinical and life sciences industries

DSG TO ATTEND ASIAN PHARMA IT SUMMIT IN SHANGHAI, CHINA

MALVERN, Pa., April. 25, 2018, DSG, Inc., a leader in eClinical software and services to the life science industry will be exhibiting at the Asian Pharma IT Summit 2018. The conference is set to take place June 12th to June 13th in Shanghai, China at the Crowne Plaza Century Park. The Asian Pharma IT Summit stands as one of the most respected and anticipated conferences throughout the pharmaceutical technological world. DSG is attending for the first time as it seeks to increase its presence in the emerging Asian region.

FDA APPROVES NANOCOATED CORONARY STENT SYSTEM USING DSG’s eClinical System Software.

MALVERN, Pa., March 23, 2017, CeloNova Biosciences, Inc. leveraging products and services provided by DSG Inc., a leading eClinical software technology and data management global services firm, has recently received US Food and Drug Administration (FDA) approval of its first-in-class COBRA PzF ™ NanoCoated Coronary Stent System.

DSG’s eCaseLink EDC allowed CeloNova Biosciences to manage subject enrollment and capture data efficiently in the global clinical trial of the COBRA PzF Coronary Stent. DSG handled all aspects of clinical study data management from database setup through lock.DSG's data management team added value to their eCaseLink EDC solution by providing CeloNova Biosciences with clean, timely, and cost-effective deliverables and week-to-week metrics showing their own progress throughout the lifespan of the study,” said Mark Barakat, MD, Senior Director, Medical Affairs at CeloNova.

DSG, INC. ACCELERATES GROWTH WITH OPENING OF NEW OFFICE IN BANGALORE, INDIA

MALVERN, Pa., Bangalore, India, January 2017 — DSG, Inc., leading provider of eClinical technology solutions, data management, professional services and customer support recently opened a new office in Bangalore, India, to accommodate rapid growth and better serve client needs. DSG's Bangalore office will complement its existing facility located in Noida, India. DSG Bangalore’s state-of-the-art facility will occupy a floor in the Prestige Shantiniketan building. The new office space will accommodate over 300 people and support the company’s growth strategy.

ORBUS THERAPEUTICS, INC. SELECTS DSG, INC. FOR EDC & IWRS IN RECURRENT ANAPLASTIC ASTROCYTOMA CLINICAL STUDY

MALVERN, Pa., September 30, 2016 — Orbus Therapeutics, Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, has selected DSG, a leader in electronic data capture (EDC).

SUPERNUS PHARMACEUTIACALS SELECTS DSG FOR EDC AND IWRS PHASE 3 CLINICAL STUDIES

MALVERN, Pa., April 01, 2016, — DSG was selected by Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to provide a fully supported eCaseLink EDC system, including IWRS Web-based Randomization-Clinical Supply, a Central lab and third-party CRO data integration, and data management services for two blinded Phase 3 clinical studies on impulsive aggression in pediatric patients being treated for Attention Deficit/Hyperactivity Disorder (ADHD).

DSG, INC. PARTNERS WITH BEDROCAN CANADA AND TWEED IN A NON-INTERVENTIONAL UNBLINDED STUDY TO EVALUATE QUALITY OF LIFE IN PATIENTS TREATED WITH MEDICAL MARIJUANA

MALVERN, Pa., February 16, 2016,— DSG has teamed up with Canada’s leading licensed producers of medical grade marijuana, Bedrocan Canada Inc. and Tweed Inc., subsidiaries of Tweed Marijuana Inc., to provide EDC and Electronic Patient Reported Outcomes (ePRO) services for the companies’ current large-scale in-country clinical study, the largest of its kind. The primary objective of the study, which is intended to continue for three years, include more than 50 sites, and enroll up to 6,000 patients, is to evaluate the quality of life (QoL) of patients before and after treatment with medical cannabis.

INTEGRIUM ENTERS INTO A MULTI-YEAR ENTERPRISE AGREEMENT WITH DSG, INC.

MALVERN, Pa., May 28, 2015, — DSG announced Integrium has signed an Enterprise Licensing Agreement for DSG’s eCaseLink solutions and services.“After years of using DSG’s highly regarded EDC platform, we’re delighted at the opportunity of being able to offer DSG’s eCaseLink EDC directly to our clients along with the integrated CTMS, Site Payment, Protocol Deviation and Safety System Modules that unify and simplify the logistics of electronic trial management within a single enterprise system. We believe that these unified modules and accompanying cutting-edge features like Risk-Based monitoring not only increase our efficiency, but enable us to provide more comprehensive, cost-effective and selective solutions to our clients,” said David Smith, MD.

SPECTRUM PHARMACEUTICALS SELECTS DSG FOR BLENDED SAAS & TECH TRANSFER EDC

MALVERN, April 28, 2015, – Spectrum Pharmaceuticals for its Phase 3 pivotal oncology studies over the past three years, has engaged DSG for full service EDC, IWRS and data management services, including a rescue study. Recently, Spectrum personnel trained on DSG’s Designer tool to begin building earlier phase studies independently of DSG.

DSG, INC PARTNERS WITH SOLIGENIX TO BATTLE CUTANEOUS T-CELL LYMPHOMA

MALVERN, Pa., April 7, 2015 – DSG, a leader in electronic data capture (EDC), has teamed up with Soligenix to provide EDC, IWRS Web-based patient randomization and data management services for their current Phase 3 clinical study of SGX301 (synthetic hypericin) coupled with visible light activation in the treatment of Cutaneous T-Cell Lymphoma.

DRUG APPROVED IN PIVOTAL STUDIES USING DSG’S FULLY ELECTRONIC SOURCE DATA

MALVERN, Pa.,March 3, 2015 – DSG, Inc and Sirion Therapeutics collaborated in launching the industry’s first two pivotal Phase 3 studies using entirely electronic source data collection for the safety and efficacy of Difluprednate in the management of inflammation following ocular surgery.

DSG DEVELOPS ACCELERATED PROJECT TEAM

MALVERN, Pa., January 29, 2015 DSG has announced today the formation of an internal team and process known as FAST to develop and launch high functioning EDC systems for Sponsors who need extraordinarily rapid eClinical system implementations.